Franklin Lakes-based Becton Dickinson and Co., a medical technology company, announced it has acquired TVA MEdical Inc., a developer of minimally invasive solutions for patients with chronic kidney disease requiring hemodialysis.
The addition of TVA will enable BD to advance its solutions for chronic kidney disease. it will now offer the everlinQ endoAVF System, a new endovascular arteriovenous fistula creation technology that adds to BD’s End-Stage Renal Disease portfolio.
“The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring hemodialysis,” said Steve Williamson, worldwide president of Peripheral Intervention at BD. “This technology is highly complementary to our Peripheral Intervention offerings, and we will continue to bring new technologies to market that improve our category-leading ESRD portfolio. This is a great example of our continued strategy to use tuck-in acquisitions to advance category leadership.”
Financial terms of the deal were not disclosed.
“The FDA’s authorization and joining BD are the culmination of many years of hard work by a dedicated team of innovators at TVA Medical, and I’d like to thank them for their tireless efforts to get us to these important milestones,” said Adam L. Berman, co-founder of TVA Medical. “BD will enable us to deliver to physicians and patients what we believe is a highly-desirable and transformative endovascular technology as an integral part of a broader ESRD-focused portfolio of solutions. I look forward to the next chapter of our history as part of the BD family.”
